"The conventional SARS-CoV-2 vaccine’s ability to provide immunological protection may be significantly impacted by over-vaccination. If this happens, either newly diagnosed COVID-19 cases or people who have already contracted the virus again may have a more severe case of the illness. This concept was proposed after seeing tolerance of both the humoral and cellular immune responses to prolonged booster immunization doses."
Molnupiravir, the oral pill for COVID-19, may actually be driving the emergence of new, potentially harmful, variants of the virus, according to a Wellcome Trust-funded study at the pre-print stage.
Since Beijing announced it is reopening China’s borders, Hong Kong announced that beginning on Dec. 29, most of the pandemic measures will be lifted but the mask mandate will remain in effect.